Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 412-419, September 2010

Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment

  • Danielle C. Whitehair

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • ,
  • Abdullah Sherzai

      Affiliations

    • Loma Linda University Medical Center, Riverside, CA, USA
    • ,
  • Jennifer Emond

      Affiliations

    • Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    • ,
  • Rema Raman

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • Department of Family and Preventive Medicine, University of California, San Diego, CA, USA
    • ,
  • Paul S. Aisen

      Affiliations

    • Department of Neurosciences, University of California, San Diego, CA, USA
    • ,
  • Ronald C. Petersen

      Affiliations

    • Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    • ,
  • Adam S. Fleisher

      Affiliations

    • Banner Alzheimer's Institute, Phoenix, AZ, USA
    • Corresponding Author InformationCorresponding author. Tel.: 602 239-6979; Fax: 602 239-6499.
    • ,
  • Alzheimer's Disease Cooperative Study

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 For all authors there are no disclosures to be made of any financial support from, or equity positions in, manufacturers of drugs or products mentioned in the manuscript. These authors and the Alzheimer's Disease Cooperative study had full publication rights without influence or restrictions from the Institute for the Study of Aging, Pfizer Inc., or Eisai Inc. All authors have agreed to conditions noted on the Author Disclosure Form. All of the authors have been instrumental in the interpretation and presentation of data in this paper. This manuscript has not been simultaneously submitted for publication to any other journal.

 Financial disclosure: Danielle C. Whitehair, Jennifer Emond, Rema Raman, Adam S. Fleisher: none. Abdullah Sherzai is a speaker for Novartis (Exelon patch); Paul S. Aisen consults with pharmaceutical companies regarding AD drug development, including Elan, Wyeth, Eisai, Neurochem, Schering-Plough, Bristol Myers Squibb, Lilly, Neurophage, Merck, Roche, Amgen, Genentech, Abbott, Pfizer, Novartis and Medivation; Ronald C. Petersen consults with pharmaceutical companies regarding AD drug development, including Elan, GE Healthcare and Wyeth. He also is a speaker for Eisai, Janssen, Novartis and Pfizer.

PII: S1552-5260(10)00002-6

doi:10.1016/j.jalz.2009.12.003

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 412-419, September 2010

Article Tools

* Image Usage & Resolution